Wall Street analyst estimates for Pluri Inc. (PLUR): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | |||
| 2026-09-10 | $-0.54 | $-0.66 | +18.2% |
| 2026-05-14 | $-0.55 | $-0.66 | +16.7% |
| 2026-02-12 | $-0.71 | $-0.65 | -9.2% |
| 2025-11-12 | $-0.65 | $-0.74 | +12.2% |
| 2025-09-17 | $-2.62 | $-0.65 | -303.1% |
| 2025-05-13 | $-0.94 | $-0.73 | -28.8% |
| 2025-02-11 | $-0.53 |
Valuation Ratios
| Price / Book | -0.55 |
| EV / EBITDA | -1.72 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | $50000 | $54000 | $23000 | 0 | $234000 | $287000 | $326000 | $1.3M | $1.0M |
| Cost of Revenue | $2.2M | $2000 | $2000 | $1.6M | $1.4M | $1.1M | $9000 | $4000 | $682000 | $563000 |
| Gross Profit | -$2.2M | $48000 | $52000 | -$1.5M | -$1.4M | -$819000 | $278000 | $322000 | $654000 | $453000 |
| Research & Development | $21.1M | $22.6M | $24.6M | $20.1M | $30.1M | $24.4M | $15.7M | $12.4M | $12.9M | $15.3M |
| Selling, General & Admin | $6.9M | $11.2M | $9.2M | $7.8M | $20.6M | $17.4M | $11.8M | $10.0M | $10.0M | $10.3M |
| Operating Expenses | $28.0M | $33.8M | $35.6M | $27.9M | $49.3M | $40.8M | $27.5M | $22.5M | $22.8M | $25.4M |
| Operating Income | -$28.0M | -$33.7M | -$35.5M | -$29.5M | -$50.6M | -$41.6M | -$27.2M | -$22.2M | -$22.2M | -$24.9M |
| EBITDA | -$25.6M | -$24.1M | -$33.3M | -$27.4M | -$48.4M | -$39.4M | -$27.7M | -$20.2M | -$22.1M | -$24.4M |
| Interest Expense | 0 | $937000 | $29000 | $196000 | $78000 | $887000 | $843000 | $866000 | $873000 | -$932000 |
| Pre-tax Income | -$27.8M | -$26.1M | -$35.3M | -$29.2M | -$49.9M | -$41.4M | -$28.9M | -$21.3M | -$23.3M | -$25.4M |
| Income Tax | -$205000 | 0 | -$94000 | 0 | 0 | 0 | 0 | 0 | -$5000 | -$25000 |
| Net Income | -$27.8M | -$26.1M | -$35.3M | -$29.2M | -$49.9M | -$41.2M | -$28.3M | -$20.9M | -$22.6M | -$23.8M |
| EPS | $-25.45 | $-19.74 | $-23.20 | $-12.80 | $-14.19 | $-10.24 | $-6.18 | $-3.99 | $-3.56 | $-2.44 |
| EPS (Diluted) | $-25.45 | $-19.74 | $-23.20 | $-12.80 | $-14.19 | $-10.24 | $-6.18 | $-3.99 | $-3.56 | $-2.44 |
| Shares Outstanding (Diluted) | $1.1M | $1.3M | $1.5M | $2.3M | $3.5M | $4.0M | $4.6M | $5.2M | $6.3M | $9.7M |
Price
| Price | $1.14 |
| Market Cap | $12M |
| Exchange | NASDAQ |
| Country | IL |
Related companies: ANTX · BOLD · IBIO · INTS · ITRM · JSPR · NXTC
Explore sector: Healthcare · Biotechnology
More sections of PLUR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks